Long-Acting HIV Therapy
Cutting-Edge Concepts in HIV Care: Long-Acting Therapies

Released: November 14, 2022

Expiration: November 13, 2023

Activity

Progress
1
Course Completed

In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including:

  • Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)
  • Risk factors for virologic failure of LA CAB + RPV
  • The ATLAS-2M study
  • Combined clinical trials of LA CAB + RPV
  • Practical considerations for LA CAB + RPV
  • Implementation of LA CAB + RPV
  • Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension study
  • Supporting candidates for LA antiretroviral therapy (ART)
  • Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San Francisco
  • Future LA ART
  • The investigational LA HIV capsid inhibitor lenacapavir (LEN)
  • LEN resistance from the CAPELLA and CALIBRATE studies
  • LEN injection-site reactions in the CAPELLA and CALIBRATE studies